HC Wainwright & Co. Maintains Buy on Lyell Immunopharma, Lowers Price Target to $39

Benzinga · 1d ago
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Lyell Immunopharma (NASDAQ:LYEL) with a Buy and lowers the price target from $45 to $39.